Balloon-expandable transfemoral transcatheter aortic valve implantation with or without predilation: findings from the prospective EASE-IT TF multicentre registry
Open Access
- 1 September 2019
- journal article
- research article
- Published by BMJ in Open Heart
- Vol. 6 (2) , e001082
Abstract
Background Predilation of the native valve has long been deemed necessary in transfemoral transcatheter aortic valve implantation (TF-TAVI), despite little trial evidence to support its clinical use. As most evidence is derived from retrospective analyses of observational studies, we conducted a two-armed, prospective multicentre registry. Methods Patients undergoing TF-TAVI with the Edwards SAPIEN 3 valve, with or without balloon aortic valvuloplasty (BAV), were included and their procedural characteristics, short-term safety and short-term efficacy outcomes compared. We hypothesised that BAV may be safely omitted in many patients and omission could be associated with procedural benefits. Results Overall, 196 consecutive patients underwent TF-TAVI, 56 with BAV and 140 without. The mean age was 81.2±6.2 years, and the mean logistic EuroSCORE I was 17.1±13.6. Device success according to Valve Academic Research Consortium-2 (VARC-2) was achieved in 96.4%. The median procedural duration was shorter without BAV (56 min vs 90 min; p=0.001), as was fluoroscopy time (10 min vs 13 min; p=0.001). The need for balloon postdilation was less frequent in patients without BAV (15.7% vs 30.4%, p=0.029). There was no difference in the proportion of patients meeting the VARC-2 defined composite safety endpoint at 30 days (9.3% without vs 8.9% with BAV; adjusted OR (adjOR) 2.55; 95% CI 0.56 to 18.84) and at 6 months (15.2% without vs 16.4% with BAV; adjOR 1.66; 95% CI 0.49 to 6.55). Conclusions In the majority of patients, BAV can be safely omitted from the TAVI procedure without adverse effects. The omission of BAV is associated with shorter procedural duration and could be advantageous for the majority of patients. Trial registration number NCT02760771.Keywords
Funding Information
- Edwards Lifesciences (n.a.)
This publication has 28 references indexed in Scilit:
- Outcomes of transcatheter aortic valve replacement without predilation of the aortic valve: Insights from 1544 patients included in the SOURCE 3 registryInternational Journal of Cardiology, 2019
- Outcomes of Direct Transcatheter Aortic Valve Replacement Without Balloon Aortic Valvuloplasty Using a New Generation ValveCardiovascular Revascularization Medicine, 2019
- Impact of Direct Transcatheter Aortic Valve Replacement Without Balloon Aortic Valvuloplasty on Procedural and Clinical OutcomesJACC: Cardiovascular Interventions, 2018
- Balloon-expandable transapical transcatheter aortic valve implantation with or without predilation of the aortic valve: results of a multicentre registry†European Journal of Cardio-Thoracic Surgery, 2017
- Transfemoral aortic valve implantation of Edwards SAPIEN 3 without predilatationCatheterization and Cardiovascular Interventions, 2016
- Increased Risk of Cerebral Embolization After Implantation of a Balloon-Expandable Aortic Valve Without Prior Balloon ValvuloplastyJACC: Cardiovascular Interventions, 2015
- Usefulness of Echocardiographic Criteria for Transcatheter Aortic Valve Implantation without Balloon Predilation: A Single-Center ExperienceJournal of the American Society of Echocardiography, 2015
- Predictors of permanent pacemaker requirement after transcatheter aortic valve implantation: Insights from a Brazilian RegistryInternational Journal of Cardiology, 2014
- Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2)European Journal of Cardio-Thoracic Surgery, 2012
- Transcranial Doppler Sound Detection of Cerebral Microembolism during Transapical Aortic Valve ImplantationThe Thoracic and Cardiovascular Surgeon, 2011